Physiologic control of IDO competence in splenic dendritic cells

Babak Baban, Phillip R. Chandler, Burles A. Johnson, Lei Huang, Minghui Li, Marlon L. Sharpe, Loise M. Francisco, Arlene H. Sharpe, Bruce R. Blazar, David H. Munn, Andrew L. Mellor

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Dendritic cells (DCs) competent to express the regulatory enzyme IDO in mice are a small but distinctive subset of DCs. Previously, we reported that a high-dose systemic CpG treatment to ligate TLR9 in vivo induced functional IDO exclusively in splenic CD19+DCs, which stimulated resting Foxp3-lineage regulatory T cells (Tregs) to rapidly acquire potent suppressor activity. In this paper, we show that IDO was induced in spleen and peripheral lymph nodes after CpG treatment in a dose-dependent manner. Induced IDO suppressed local T cell responses to exogenous Ags and inhibited proinflammatory cytokine expression in response to TLR9 ligation. IDO induction did not occur in T cell-deficient mice or in mice with defective B7 or programmed death (PD)-1 costimulatory pathways. Consistent with these findings, CTLA4 or PD-1/PD-ligand costimulatory blockade abrogated IDO induction and prevented Treg activation via IDO following high-dose CpG treatment. Consequently, CD4 +CD25+ T cells uniformly expressed IL-17 shortly after TLR9 ligation. These data support the hypothesis that constitutive interactions from activated T cells or Tregs and IDO-competent DCs via concomitant CTLA4→B7 and PD-1→PD-ligand signals maintain the default potential to regulate T cell responsiveness via IDO. Acute disruption of these nonredundant interactions abrogated regulation via IDO, providing novel perspectives on the proinflammatory effects of costimulatory blockade therapies. Moreover, interactions between IDO-competent DCs and activated T cells in lymphoid tissues may attenuate proinflammatory responses to adjuvants such as TLR ligands.

Original languageEnglish (US)
Pages (from-to)2329-2335
Number of pages7
JournalJournal of Immunology
Volume187
Issue number5
DOIs
StatePublished - Sep 1 2011

Fingerprint

Mental Competency
Dendritic Cells
T-Lymphocytes
Ligands
Ligation
Interleukin-17
Lymphoid Tissue
Regulatory T-Lymphocytes
Spleen
Lymph Nodes
Cytokines
Enzymes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Baban, B., Chandler, P. R., Johnson, B. A., Huang, L., Li, M., Sharpe, M. L., ... Mellor, A. L. (2011). Physiologic control of IDO competence in splenic dendritic cells. Journal of Immunology, 187(5), 2329-2335. https://doi.org/10.4049/jimmunol.1100276

Physiologic control of IDO competence in splenic dendritic cells. / Baban, Babak; Chandler, Phillip R.; Johnson, Burles A.; Huang, Lei; Li, Minghui; Sharpe, Marlon L.; Francisco, Loise M.; Sharpe, Arlene H.; Blazar, Bruce R.; Munn, David H.; Mellor, Andrew L.

In: Journal of Immunology, Vol. 187, No. 5, 01.09.2011, p. 2329-2335.

Research output: Contribution to journalArticle

Baban, B, Chandler, PR, Johnson, BA, Huang, L, Li, M, Sharpe, ML, Francisco, LM, Sharpe, AH, Blazar, BR, Munn, DH & Mellor, AL 2011, 'Physiologic control of IDO competence in splenic dendritic cells', Journal of Immunology, vol. 187, no. 5, pp. 2329-2335. https://doi.org/10.4049/jimmunol.1100276
Baban B, Chandler PR, Johnson BA, Huang L, Li M, Sharpe ML et al. Physiologic control of IDO competence in splenic dendritic cells. Journal of Immunology. 2011 Sep 1;187(5):2329-2335. https://doi.org/10.4049/jimmunol.1100276
Baban, Babak ; Chandler, Phillip R. ; Johnson, Burles A. ; Huang, Lei ; Li, Minghui ; Sharpe, Marlon L. ; Francisco, Loise M. ; Sharpe, Arlene H. ; Blazar, Bruce R. ; Munn, David H. ; Mellor, Andrew L. / Physiologic control of IDO competence in splenic dendritic cells. In: Journal of Immunology. 2011 ; Vol. 187, No. 5. pp. 2329-2335.
@article{237918022ca34f3d9dca9e601be69e1c,
title = "Physiologic control of IDO competence in splenic dendritic cells",
abstract = "Dendritic cells (DCs) competent to express the regulatory enzyme IDO in mice are a small but distinctive subset of DCs. Previously, we reported that a high-dose systemic CpG treatment to ligate TLR9 in vivo induced functional IDO exclusively in splenic CD19+DCs, which stimulated resting Foxp3-lineage regulatory T cells (Tregs) to rapidly acquire potent suppressor activity. In this paper, we show that IDO was induced in spleen and peripheral lymph nodes after CpG treatment in a dose-dependent manner. Induced IDO suppressed local T cell responses to exogenous Ags and inhibited proinflammatory cytokine expression in response to TLR9 ligation. IDO induction did not occur in T cell-deficient mice or in mice with defective B7 or programmed death (PD)-1 costimulatory pathways. Consistent with these findings, CTLA4 or PD-1/PD-ligand costimulatory blockade abrogated IDO induction and prevented Treg activation via IDO following high-dose CpG treatment. Consequently, CD4 +CD25+ T cells uniformly expressed IL-17 shortly after TLR9 ligation. These data support the hypothesis that constitutive interactions from activated T cells or Tregs and IDO-competent DCs via concomitant CTLA4→B7 and PD-1→PD-ligand signals maintain the default potential to regulate T cell responsiveness via IDO. Acute disruption of these nonredundant interactions abrogated regulation via IDO, providing novel perspectives on the proinflammatory effects of costimulatory blockade therapies. Moreover, interactions between IDO-competent DCs and activated T cells in lymphoid tissues may attenuate proinflammatory responses to adjuvants such as TLR ligands.",
author = "Babak Baban and Chandler, {Phillip R.} and Johnson, {Burles A.} and Lei Huang and Minghui Li and Sharpe, {Marlon L.} and Francisco, {Loise M.} and Sharpe, {Arlene H.} and Blazar, {Bruce R.} and Munn, {David H.} and Mellor, {Andrew L.}",
year = "2011",
month = "9",
day = "1",
doi = "10.4049/jimmunol.1100276",
language = "English (US)",
volume = "187",
pages = "2329--2335",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Physiologic control of IDO competence in splenic dendritic cells

AU - Baban, Babak

AU - Chandler, Phillip R.

AU - Johnson, Burles A.

AU - Huang, Lei

AU - Li, Minghui

AU - Sharpe, Marlon L.

AU - Francisco, Loise M.

AU - Sharpe, Arlene H.

AU - Blazar, Bruce R.

AU - Munn, David H.

AU - Mellor, Andrew L.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Dendritic cells (DCs) competent to express the regulatory enzyme IDO in mice are a small but distinctive subset of DCs. Previously, we reported that a high-dose systemic CpG treatment to ligate TLR9 in vivo induced functional IDO exclusively in splenic CD19+DCs, which stimulated resting Foxp3-lineage regulatory T cells (Tregs) to rapidly acquire potent suppressor activity. In this paper, we show that IDO was induced in spleen and peripheral lymph nodes after CpG treatment in a dose-dependent manner. Induced IDO suppressed local T cell responses to exogenous Ags and inhibited proinflammatory cytokine expression in response to TLR9 ligation. IDO induction did not occur in T cell-deficient mice or in mice with defective B7 or programmed death (PD)-1 costimulatory pathways. Consistent with these findings, CTLA4 or PD-1/PD-ligand costimulatory blockade abrogated IDO induction and prevented Treg activation via IDO following high-dose CpG treatment. Consequently, CD4 +CD25+ T cells uniformly expressed IL-17 shortly after TLR9 ligation. These data support the hypothesis that constitutive interactions from activated T cells or Tregs and IDO-competent DCs via concomitant CTLA4→B7 and PD-1→PD-ligand signals maintain the default potential to regulate T cell responsiveness via IDO. Acute disruption of these nonredundant interactions abrogated regulation via IDO, providing novel perspectives on the proinflammatory effects of costimulatory blockade therapies. Moreover, interactions between IDO-competent DCs and activated T cells in lymphoid tissues may attenuate proinflammatory responses to adjuvants such as TLR ligands.

AB - Dendritic cells (DCs) competent to express the regulatory enzyme IDO in mice are a small but distinctive subset of DCs. Previously, we reported that a high-dose systemic CpG treatment to ligate TLR9 in vivo induced functional IDO exclusively in splenic CD19+DCs, which stimulated resting Foxp3-lineage regulatory T cells (Tregs) to rapidly acquire potent suppressor activity. In this paper, we show that IDO was induced in spleen and peripheral lymph nodes after CpG treatment in a dose-dependent manner. Induced IDO suppressed local T cell responses to exogenous Ags and inhibited proinflammatory cytokine expression in response to TLR9 ligation. IDO induction did not occur in T cell-deficient mice or in mice with defective B7 or programmed death (PD)-1 costimulatory pathways. Consistent with these findings, CTLA4 or PD-1/PD-ligand costimulatory blockade abrogated IDO induction and prevented Treg activation via IDO following high-dose CpG treatment. Consequently, CD4 +CD25+ T cells uniformly expressed IL-17 shortly after TLR9 ligation. These data support the hypothesis that constitutive interactions from activated T cells or Tregs and IDO-competent DCs via concomitant CTLA4→B7 and PD-1→PD-ligand signals maintain the default potential to regulate T cell responsiveness via IDO. Acute disruption of these nonredundant interactions abrogated regulation via IDO, providing novel perspectives on the proinflammatory effects of costimulatory blockade therapies. Moreover, interactions between IDO-competent DCs and activated T cells in lymphoid tissues may attenuate proinflammatory responses to adjuvants such as TLR ligands.

UR - http://www.scopus.com/inward/record.url?scp=80052671582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052671582&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1100276

DO - 10.4049/jimmunol.1100276

M3 - Article

C2 - 21813777

AN - SCOPUS:80052671582

VL - 187

SP - 2329

EP - 2335

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -